Intracameral sustained release bimatoprost implants (Durysta)

Sirinek, Portia; Lin, Michael

doi:10.1080/08820538.2021.1985145

Cited by 16 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Several hypotheses may explain the sustained IOP-lowering mechanism. 12 PGAs are thought to stimulate expression of matrix metalloproteinases in the trabecular meshwork and ciliary body, leading to extracellular matrix (ECM) remodeling and increasing outflow through both the conventional and unconventional pathways. Delivered in a targeted manner, the bimatoprost implant yields higher drug concentrations in the iris and ciliary body compared with topical PGAs.…”

Section: Discussionmentioning

confidence: 99%

“…However, the prolonged effect of the implant has previously been reported; in phase I/II trials, a single administration of the bimatoprost implant controlled IOP for up to 12 months in 40% of patients and up to 24 months in 28% of patients 11 . Several hypotheses may explain the sustained IOP-lowering mechanism 12 . PGAs are thought to stimulate expression of matrix metalloproteinases in the trabecular meshwork and ciliary body, leading to extracellular matrix (ECM) remodeling and increasing outflow through both the conventional and unconventional pathways.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study

Choi,

Johnson,

Stinnett

et al. 2024

Journal of Glaucoma

View full text Add to dashboard Cite

Précis: In this retrospective study of glaucoma patients receiving the bimatoprost implant at Duke Eye Center, the number of topical intraocular pressure-lowering medications was significantly reduced through 12 months after the implant. Purpose: To study the effects of the bimatoprost implant on intraocular pressure (IOP) and the need for topical IOP-lowering medications in glaucoma patients in the clinical practice setting. Patients and Methods: Patients who received the bimatoprost implant at Duke Eye Center from November 2020 to October 2021 were identified. Exclusion criteria included addition of other IOP-lowering medications concurrent with the implant and less than 1 month of follow-up. The change in IOP and number of topical IOP-lowering medications from baseline to months 1, 3, 6, 9, and 12 after the implant was calculated. Subgroup analysis was performed for different glaucoma severities. Results: A total of 63 patients and 92 eyes were included (mean age 77.8 ± 10.1 years). Glaucoma severity ranged from mild (11%), moderate (30%), to severe (54%). There was a nonsignificant decrease in IOP at all timepoints. The mean number of topical IOP-lowering medications significantly decreased by 0.81, 0.75, 0.63, 0.70, and 0.67 at month 1, 3, 6, 9, and 12, respectively (all P < 0.001). There was no significant change in the total number of medications including the bimatoprost implant. When divided by glaucoma severity, the reduction in the number of topical medications was significant at 1, 3, and 6 months for mild/moderate disease, and at 1 month for severe disease. During the follow-up period, 19 eyes underwent additional laser or surgical procedures, 68% of which had a history of prior incisional glaucoma surgery. Conclusions: The bimatoprost implant may reduce the need for topical IOP-lowering agents over a 1-year period, especially in mild-to-moderate stage glaucoma. The efficacy of the implant may be more limited in severe glaucoma, and further work is needed to characterize its long-term effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study

Choi,

Johnson,

Stinnett

et al. 2024

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…More recently (see Table 3 for current FDA-approved ophthalmic SRDD options), the prostaglandin analog bimatoprost has been formulated as a preservative-free anterior chamber implant (Durysta, Allergan, an AbbVie Company). The bimatoprost SR (sustained release) implant can be administered in the office setting and can improve or eliminate nonadherence by lowering IOP for up to 6 months [188], although because of corneal safety concerns is indicated for one-time use only [189]. Multiple other novel SRDD platforms for glaucoma management are in various stages of development [178,179 ▪ ,180,190 ▪ ].…”

Section: Approaches To Improve Adherencementioning

confidence: 99%

Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy

Hovanesian

Singh²,

Bauskar³

et al. 2023

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewTo discuss common reasons for nonadherence and review existing and emerging options to reduce nonadherence with ocular medical therapy and optimize therapeutic outcomes.Recent findingsNonadherence can arise from patient-related issues (e.g. physical, cognitive) and healthcare-related issues (e.g. cost, access to care). Multiple strategies have been developed and evaluated to overcome these barriers to adherence. Identifying nonadherence and its cause(s) facilitates the development of strategies to overcome it.SummaryMany common causes of nonadherence can be mitigated through a variety of strategies presented.

show abstract

“…In 2020, researchers also shared favorable efficacy and safety profiles over 24 months following implantation [ 75 ]. Durysta delivers bimatoprost using a solid polymer platform for drug delivery composed of the aliphatic polyesters poly(D,L-lactide), poly(D,L-lactide-co-glycolide), poly(D,L-lactide) acid end, and polyethylene glycol 3350 [ 88 , 89 ]. The implant was approved by the United States FDA in March 2020 for the treatment of open-angle glaucoma and ocular hypertension [ 89 ].…”

Section: Ocular Implantsmentioning

confidence: 99%

Biomaterial Drug Delivery Systems for Prominent Ocular Diseases

et al. 2023

View full text Add to dashboard Cite

Ocular diseases, such as age-related macular degeneration (AMD) and glaucoma, have had a profound impact on millions of patients. In the past couple of decades, these diseases have been treated using conventional techniques but have also presented certain challenges and limitations that affect patient experience and outcomes. To address this, biomaterials have been used for ocular drug delivery, and a wide range of systems have been developed. This review will discuss some of the major classes and examples of biomaterials used for the treatment of prominent ocular diseases, including ocular implants (biodegradable and non-biodegradable), nanocarriers (hydrogels, liposomes, nanomicelles, DNA-inspired nanoparticles, and dendrimers), microneedles, and drug-loaded contact lenses. We will also discuss the advantages of these biomaterials over conventional approaches with support from the results of clinical trials that demonstrate their efficacy.

show abstract

Intracameral sustained release bimatoprost implants (Durysta)

Cited by 16 publications

References 18 publications

The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study

The Effect of Bimatoprost Implant on Glaucoma Patients: An Observational Study

Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy

Biomaterial Drug Delivery Systems for Prominent Ocular Diseases

Contact Info

Product

Resources

About